Table 4 Matrix table of annualised relapse rate ratios (standard errors) for an NMA of all RCTs, including the simulated TRANFORMS and FREEDOMS studies (above the diagonal) and those obtained from the NMA of the simulated RCTs and RWE combined (below the diagonal). Results presented at face value with no adjustments made for the inclusion of RWE
From: The inclusion of real world evidence in clinical development planning
| Â | Placebo | Nataluzimab | Fingolimod 1.25 | Fingolimod 0.5 | Avonex | Rebif 22 | Rebif 44 | Copaxone | Betaferon |
|---|---|---|---|---|---|---|---|---|---|
Placebo | Â | 0.319 (0.05) | 0.519 (0.05) | 0.465 (0.05) | 0.916 (0.09) | 0.783 (0.10) | 0.706 (0.07) | 0.667 (0.06) | 0.686 (0.07) |
Nataluzimab | 0.420 (0.08) | Â | 1.666 (0.31) | 1.492 (0.28) | 2.940 (0.54) | 2.370 (0.54) | 2.265 (0.42) | 2.140 (0.39) | 2.157 (0.41) |
Fingolimod 1.25 | 0.497 (0.07) | 1.210 (0.28) | Â | 0.901 (0.09) | 1.781 (0.22) | 1.437 (0.25) | 1.373 (0.20) | 1.297 (0.18) | 1.335 (0.19) |
Fingolimod 0.5 | 0.448 (0.07) | 1.103 (0.26) | 0.913 (0.13) | Â | 1.989 (0.25) | 1.606 (0.28) | 1.534 (0.22) | 1.450 (0.20) | 1.491 (0.22) |
Avonex | 0.831 (0.08) | 2.039 (0.40) | 1.703 (0.27) | 1.886 (0.30) | Â | 0.811 (0.13) | 0.774 (0.09) | 0.732 (0.09) | 0.753 (0.09) |
Rebif 22 | 0.798 (0.10) | 1.957 (0.40) | 1.639 (0.30) | 1.814 (0.33) | 0.965 (0.11) | Â | 0.920 (0.14) | 0.920 (0.14) | 0.945 (0.16) |
Rebif 44 | 0.781 (0.10) | 1.914 (0.38) | 1.604 (0.29) | 1.776 (0.32) | 0.944 (0.11) | 0.987 (0.13) | Â | 0.951 (0.10) | 0.980 (0.13) |
Copaxone | 0.614 (0.06) | 1.507 (0.30) | 1.261 (0.21) | 1.396 (0.23) | 0.743 (0.08) | 0.777 (0.10) | 0.794 (0.10) | Â | 1.033 (0.10) |
Betaferon | 0.728 (0.08) | 1.788 (0.35) | 1.496 (0.25) | 1.656 (0.28) | 0.881 (0.08) | 0.921 (0.10) | 0.941 (0.11) | 1.193 (0.12) | Â |